Supplemental Online Content

Lee JW, Wang W, Rezk A, et al. Hypotension and adverse outcomes in moderate to severe traumatic brain injury: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(11):e2444465. doi:10.1001/jamanetworkopen.2024.44465

- eAppendix. Definitions of TBI and Hypotension
- eTable 1. Search Strategy
- eTable 2. Definition of Continuous and Categorical Variables
- eTable 3. Reported Management Strategies for Hypotension
- eTable 4. Adjusted Factors for Calculation of Adjusted Odds Ratios
- eTable 5. Quality Assessment Using Newcastle-Ottawa Scale for Cohort Studies
- eTable 6. Heterogeneity Analysis for Continuous Variables
- eTable 7. Heterogeneity Analysis for Categorical Variables
- eTable 8. Leave-One-Out Analysis for Studies Reporting Adjusted OR
- eTable 9. Leave-One-Out Analysis for Studies Reporting Crude OR
- eTable 10. Heterogeneity Analysis for Substudies Using Multilevel Meta-Analysis
- **eFigure 1.** Forest Plot Showing Crude Association of Hypotension on Adverse Outcome in Patients With Moderate to Severe Traumatic Brain Injury
- **eFigure 2.** Forest Plot Showing Incidence of Hypotension by Subgroups in Patients With Moderate to Severe Traumatic Brain Injury
- **eFigure 3.** Forest Plot Showing Association of Hypotension on Adverse Outcome in Patients With Moderate to Severe Traumatic Brain Injury
- eFigure 4. Funnel Plot for Publication Bias
- eFigure 5. Galbraith Plot for Exhibiting Outliers
- eFigure 6. Trim Fill Funnel Plot for Publication Bias

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix: Definitions of TBI and hypotension.

TBI is defined as any neurological insult secondary to penetrating or blunt trauma to the head. TBI severity is categorized into mild, moderate, or severe. TBI severity is commonly assessed using one of two scoring systems (TBI Scale); the abbreviated injury (AIS) scores and/or Glasgow coma scale (GCS) scores. AIS score of 2,3+, or a GCS score within 9-12, and 3-8 corresponds to moderate and severe TBI respectively. 67.88

Hypotension in the setting of TBI can be defined using different measurements. SBP is a common mode of measurement. For the purpose of this study, hypotension was defined as a SBP < 90mmHg. Other hypotension thresholds were included if study authors utilized a different threshold for hypotension (i.e., <110 mmHg, <100 mmHg, etc.) and/or in cases where study authors identified a SBP threshold which had a significant association with adverse outcome(s). Setting of hypotension measurement is defined as the location of measurement within patient management and care of TBI which include: emergency medical services (EMS), hospital (ED) arrival, and during ICU care.

eTable 1: Search Strategy

MEDLINE

Ovid MEDLINE(R) 1946 to April 04, 2024

| # | Searches |
|----|--|
| 1 | exp Hypotension/ |
| 2 | exp Cerebrovascular Circulation/ |
| 3 | Blood Pressure Determination/ |
| 4 | exp Blood Pressure/ |
| 5 | (arter* pressure? adj8 (diastolic or systolic)).mp. |
| 6 | (blood pressure? and (low* or abnormal* or challeng* or deficien* or drop*4 or restor*)).mp. |
| 7 | brain blood flow*.mp. |
| 8 | cerebral perfusion pressure?.mp. |
| 9 | cerebral* blood flow*.mp. |
| 10 | cerebral* circulation?.mp. |
| 11 | cerebrovascular* circulation*.mp. |
| 12 | diastolic pressure?.mp. |
| 13 | hypotensi*.mp. |
| 14 | pulse pressure?.mp. |
| 15 | systolic pressure?.mp. |
| 16 | "60 millimeter? of mercury".mp. |
| 17 | "60 mm Hg?".mp. |
| 18 | "60 mmHg?".mp. |
| 19 | "60mmHg?".mp. |
| 20 | "90 millimeter? of mercury".mp. |
| 21 | "90 mm Hg?".mp. |
| 22 | "90 mmHg?".mp. |
| 23 | "90mmHg?".mp. |
| 24 | ("90/60" and (diastolic or systolic)).mp. |
| 25 | or/1-24 [Hypotension & related Terms] |
| 26 | exp Brain Injuries/ |

| 27 | exp Brain Concussion/ |
|----|---|
| 28 | Coma, Post-Head Injury/ |
| 29 | Contrecoup Injury/ |
| 30 | Craniocerebral Trauma/ |
| 31 | Glasgow Coma Scale/ and (exp Accidents/ or (accident* or injur* or insult? or event? or trauma*).mp.) |
| 32 | Glasgow Outcome Scale/ and (exp Accidents/ or (accident* or injur* or insult? or event? or trauma*).mp.) |
| 33 | exp Head Injuries, Closed/ |
| 34 | Head Injuries, Penetrating/ |
| 35 | exp Intracranial Hemorrhage, Traumatic/ |
| 36 | Persistent Vegetative State/ |
| 37 | exp Skull Fractures/ |
| 38 | Subarachnoid Hemorrhage, Traumatic/ |
| 39 | ((brain? adj3 injur*) and (accident* or trauma*)).ti,ab. |
| 40 | (closed adj3 head adj2 injur*).mp. |
| 41 | (closed adj3 head adj2 traum*).mp. |
| 42 | (coup adj3 injur*).mp. |
| 43 | (craniocerebral* adj1 trauma*).mp. |
| 44 | (cranio-cerebral* adj1 trauma*).mp. |
| 45 | (diffuse adj1 axon* adj1 injur*).mp. |
| 46 | (Glasgow adj2 coma* adj10 (accident* or injur* or insult? or event? or trauma*)).mp. |
| 47 | (head adj2 injur*).mp. |
| 48 | (head adj2 trauma*).mp. |
| 49 | (head? adj1 impact*).mp. |
| 50 | (injur* adj3 (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |
| 51 | (insult* adj3 (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |
| 52 | (second* adj2 impact* adj1 syndrom*).mp. |
| 53 | (skull* adj2 fractur*).mp. |
| 54 | (subarachnoid* adj2 h?emorrhage? adj10 (accident* or injur* or insult? or crash* or traffic* or trauma*)).mp. |
| 55 | (trauma* adj4 (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |

| 56 | (traumatic* adj2 encephalopath*).mp. |
|----|--|
| 57 | commotio cerebri.mp. |
| 58 | concuss*.mp. |
| 59 | contre-coup.mp. |
| 60 | (contre-coup* and (head? or brain* or cranial* or cranium or skull?)).mp. |
| 61 | (contrecoup* and (head? or brain* or cranial* or cranium or skull?)).mp. |
| 62 | (contusion* and (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |
| 63 | coup-contrecoup injur*.mp. |
| 64 | ((mtbi or mtbis) and (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |
| 65 | (neuro-trauma* and (head? or brain* or cerebr* or cerebell* or cranial* or cranium or skull?)).mp. |

eTable 2: Definition of continuous and categorical variables.

| Variable | Definition |
|-------------------------------------|---|
| Categorical Sample size group | Studies were divided into four groups based on sample size for subgroup and sensitivity analysis (<200, 201- 1000, 1001-5000, >5000) |
| TBI severity | TBI injury was categorized by severity based on GCS and AIS score thresholds as outlined in the definitions section. TBI severity was categorized as moderate only, severe only, and moderate-severe |
| TBI scale | Degree and severity of TBI injury is often classified using GCS or AIS scoring systems. TBI scale was categorized as either GCS or AIS depending on the scale used by the study to define moderate, severe, or moderate-severe TBI |
| Location | The location/setting initial blood pressure measurement was performed in the study. Blood pressure setting was categorized into emergency medical services/ambulance/pre-hospital (EMS), emergency department (ED), intensive care unit (ICU) or intraoperative (IOP). In the event study measured blood pressure in EMS, ED and ICU settings, setting was categorized as ALL |
| Trauma type | Studies were categorized based on the type of trauma patients included in the study. Type was categorized as isolated if study only included traumatic brain injury patients with no other injury site on the body. Alternatively, studies were categorized as polytrauma if it included TBI patients with other body injury sites |
| Blood pressure category | • Thresholds were categorized for subgroup analysis (<90 mmHg, 90 mmHg, >90 mmHg) |
| Age category | • Studies were divided into four groups based on mean age (<40, 40-50, 50-60, >60) |
| Hypoxia adjusted | Studies in which hypoxia was measured and adjusted for calculating their adjusted odds ratios |
| Continuous Total sample size | • Total sample size of the study |
| Mean age | Mean age of the study |
| Male % | Proportion of males which make up the total sample size |
| Blood pressure cutoff | • The range of blood pressure between 0 and the study's stated threshold |

eTable 3: Reported management strategies for hypotension

| G. I | |
|----------------------------|------------------------|
| Study | Hypotension management |
| Aiolfi 2017 | N/A |
| Aiolfi 2018 | N/A |
| Asmar 2021 | N/A |
| Brorsson 2011 | N/A |
| Chamoun 2009 | 1, 2 |
| Chen 2019 | N/A |
| Corral 2012 | 1, 2 |
| Czorlich 2017 | 1 |
| DuBose 2008 | N/A |
| Farahvar 2011 | 1 |
| Farahvar 2012 | 1 |
| Franschman 2011 | 1, 2 |
| Fuller 2014 | N/A |
| Hartl 2008 | 1, 2 |
| Hasanin 2016 | N/A |
| Heppekcan 2019 | 1, 2 |
| Herrera-Melero 2015 | 1, 2 |
| Huang 2022 | N/A |
| Hukkelhoven 2005 | N/A |
| Jacobs 2013 | N/A |
| Kamal 2016 | N/A |
| Kamal 2021 | N/A |
| Khalili 2017 | 1, 2 |
| Kim 2018 | 1, 2 |
| Krishnamoorthy 2015 | N/A |
| Lenstra 2020 | N/A |
| Manley 2001 | 1, 2, 3 |
| Merck 2019 | 1, 2, 3 |
| Muehlschlegel 2013 | 1, 2 |
| Newgard 2015 | 1, 3 |
| Para 2018 | 1, 2 |
| Petroni 2010 | 1, 2 |
| Pin-On 2017 | 1, 3 |
| Rauch 2021 | 1, 2 |
| Rice 2023 | 1 |
| Schellenberg 2021 | N/A |
| Shafi 2005 | 1 |
| Shibahashi 2017 | 1 |
| Shibahashi 2018 | 1 |
| Shibahashi 2021 | 1 |
| Song 2023 | 3 |
| Spaite 2017 ^a | N/A |
| Spaite 2017 ^b | N/A |
| Spaite 2017 ^c | N/A |
| Spaite 2017 Spaite 2022 | N/A |
| Tohme 2014 | 1 |
| Utomo 2009 | N/A |
| Vos 2010 | N/A |
| Yeung 2021 | N/A N/A |
| Zafar 2011 | N/A |
| Zeiler 2021 | 1, 2 |
| ZCHCI ZUZ I | 1, 4 |

Legend: 1 = fluids, 2 = vasopressor, 3 = transfusion. a,b,c indicates separate studies from same author and year,

eTable 4: Adjusted factors for calculation of adjusted odds ratios

| Study | Adjusted factors |
|---------------------------|--|
| Aiolfi 2017 | Age, sex, comorbidities, hypotension, tachycardia, GCS, AIS3, AIS4, AIS5, prehospital intubation, level 1 trauma center, transport time, HEMS |
| Aiolfi 2018 | Age, hypotension on admission, GCS, prehospital intubation, H-AIS 4, H-AIS 5 |
| Asmar 2021 | Patient demographics, vital signs, injury parameters |
| Chen 2019 | Age, sex, race, insurance status, transport mode, mechanism of injury, ISS, prehospital SBP, admission SBP, need for urgent operation, mechanical ventilation, in-hospital complications, and trauma center level |
| Czorlich 2017 | Age, BMI, GCS, injury pattern, pre-hospital CPR, blood pressure, ISS, head injury |
| DuBose 2008 | Age, ACS level, mechanism, ISS, hypotension, and GCS |
| Farahvar 2011 | Age, day 1 hypotension status, day 1 pupillary status, initial gcs score, CT scan results |
| Farahvar 2012 | Age, hours of ICP > 25 mm Hg in the first 24 hours, GCS score, pupillary abnormalities, CT findings (partial open/closed cisterns or ≥0.5-cm midline shift) |
| Franschman 2011 | Age, pupillary reactivity, and GCS, hypoxia, hypotension, ISS |
| Fuller 2014 ^a | Age, ISS, admission GCS, Marshall Score, hypoxia, traumatic subarachnoid hemorrhage |
| Huang 2022 | Patient demographics, injury parameters, vital signs |
| Hukkelhoven 2005 | Age, motor score, pupillary reactivity, hypoxia, hypotension, CT parameters |
| Jacobs 2013 Kamal 2016 | Demographic, clinical and CT characteristics |
| Kamai 2016 | Demographics (age, gender), clinical severity (the motor GCS at admission, pupillary reactivity, limb movement and major extracranial injuries), secondary insult (hypotension) and various CT findings (midline shift, subdural haematoma, epidural haematoma (EDH), basal cistern effaced, presence of traumatic subarachnoid haemorrhage/intraventricular haematoma |
| Kamal 2021 | Demographics (age, gender), clinical severity (the motor GCS at admission, pupillary reactivity, limb movement and major extracranial injuries), secondary insult (hypotension) and various CT findings (midline shift, subdural haematoma, epidural haematoma (EDH), basal cistern effaced, presence of traumatic subarachnoid haemorrhage/intraventricular haematoma |
| Khalili 2017 | Age ≥55, selenase, gender, hypotension, GCS ≤8, Rotterdam, IVH, SAH, EDH, SDH, ICH, contusion, neurosurgical intervention, ICU LOS, hospital LOS |
| Krishnamoorthy 2015 | Age, trauma designation, teaching status, hospital size, gender, admission hypotension, admission GCS, admission ISS, and ventilator requirement during hospitalization, race, insurance status, hospital profit status, number of neurosurgeons at facility, and facility region |
| Lenstra 2020 | Age, hours of ICP higher than 25 mm Hg in the first 24 hours, GCS score, pupillary abnormalities, CT findings (partial open/closed cisterns or ≥0.5-cm midline shift) |
| Merck 2019 | O2 Sat, Temperature, ICP, Glucose, INR, Hb, CPP, MAP, Brain tissue oxygen tension, SBP |
| Newgard 2015 | Age, sex, ISS, head AIS score, initial SBP category, pulse rate category, initial GCS, advanced airway attempts, air transport, site |
| Petroni 2010 | Age, GCS, pupillary response, hypotension, presence of compression or midline shift on CT findings |
| Rice 2023 | Age, sex, race, ethnicity, payment source, trauma type (blunt or penetrating), head region, severity score (ICD-9) matched to Abbreviated Injury Scale), ISS, multisystem TBI (anybody region other than head with a severity score of at least 3), intervention of guideline implementation, prehospital hypoxia, prehospital CPR, and treating trauma center prehospital CPR, treating trauma center |
| Schellenberg 2021 | Patient demographic data (age, gender, and comorbidities), clinical data [prehospital and first ED systolic blood pressure (SBP, mmHg), heart rate (HR, beats per minute (bpm)), and GCS]; injury data [mechanism of injury, level of trauma center, Injury Severity Score (ISS), AIS by body region, and presence of drug or alcohol intoxication]; clinically relevant times (time to first CTH, time to intervention, and time spent in ED) |
| Shibahashi 2017 | Age; sex; year of admittance; GCS score on arrival at the hospital; comorbidities; hypotension (<90 mm Hg systolic) on arrival; RTS; ISS; whether head CT was performed for initial surveying; nature of the head injury |
| Shibahashi 2018 | Age, sex, year of hospital admittance, Glasgow Coma Scale score on arrival, Injury Severity Score, major extracranial injuries, maximum head AIS score |
| Shibahashi 2021 | Age, sex, year of hospital admission, time of day, nature of the injury, prehospital Japan Coma Scale, maximum head AIS score, ISS |
| Spaite 2017 ^a | Age, sex, race, ethnicity, Injury Severity Score (ISS), and head region injury score (H-AIS), Trauma type (blunt versus penetrating), payment source, treating TC |
| Spaite 2017 ^b | Age, sex, race, ethnicity, Injury Severity Score (ISS), and head region injury score (H-AIS), interfacility transfer, trauma type (blunt versus penetrating), payment source, treating TC |
| Spaite 2017 ^c | Age, sex, race, ethnicity, payment source, trauma type (blunt/penetrating), prehospital hypoxia, prehospital intubation, treating trauma center |

eTable 5: Quality assessment using Newcastle-Ottawa Scale for Cohort Studies

| Study ID | Author | Year | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Quality |
|----------|-----------------------|------|---|---|---|---|---|---|---|---|--------|---------|
| #57 | Rice et al | 2023 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 8 | Good |
| #132 | Huang et al. | 2022 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 | Fair |
| #184 | Yang et al | 2022 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #325 | Rauch et al | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 6 | Fair |
| #373 | Shibahashi et al | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | Good |
| #387 | Kamal et al | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #416 | Gaitanidis et al | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #440 | Asmar et al | 2021 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 | Fair |
| #444 | Zeiler et al | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #454 | Schellenberg et al | 2021 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 5 | Fair |
| #713 | Heppekcan et al | 2019 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 5 | Fair |
| #268 | Reza Bagheri et al | 2021 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #741 | Chen et al | 2019 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 5 | Fair |
| #179 | Spaite et al. | 2022 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 8 | Good |
| #874 | Shibahashi et al | 2018 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | Good |
| #537 | Gao et al. | 2020 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | Good |
| #779 | Merck et al. | 2019 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 7 | Good |
| #787 | Pakkanen et al | 2019 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 | Good |
| #999 | Aiolfi et al | 2018 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #1025 | Kim et al | 2018 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1093 | Czorlich et al | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1102 | Shibahashi et al | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1109 | Khalili et al. | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1128 | Spaite et al. | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1183 | Aiolfi et al | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1204 | Spaite et al. | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1222 | Spaite et al. | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1345 | Hasanin et al. | 2016 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1474 | Herrera-Melero et al. | 2015 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1561 | Newgard et al. | 2015 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #1726 | Tohme et al. | 2014 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1741 | Fuller et al. | 2014 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1887 | Muehlschlegel et al. | 2013 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #1917 | Jacobs et al. | 2013 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 5 | Fair |
| #1971 | Farahvar et al | 2012 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #2193 | Zafar et al. | 2011 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 | Good |
| #2193 | Franschman et al. | 2011 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #2223 | Farahvar et al. | 2011 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #2262 | Vos et al. | 2011 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #2337 | Petroni et al. | 2010 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| | | | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 9 7 | Good |
| #2457 | Utomo et al. | 2009 | | | | | | | | | | |
| #2486 | Chamoun et al. | 2009 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #2563 | DuBose et al. | 2008 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #2599 | Steyerberg et al. | 2008 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #2606 | Hartl et al. | 2008 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 6 | Fair |
| #2606 | Chi et al. | 2008 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | Fair |

| #2961 | Shafi et al. | 2005 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
|--------|-----------------------|------|---|---|---|---|---|---|---|---|---|------|
| #2994 | Hukkelhoven et al. | 2005 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #3449 | Manley et al. | 2001 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| #4974 | Lenstra et al | 2020 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #5031 | Para et al. | 2018 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #5108 | Krishnamoorthy et al. | 2015 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #9550 | Yeung et al. | 2021 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #13506 | Asmar et al. | 2021 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |
| #14404 | Pin-On et al. | 2017 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #20083 | Song et al. | 2023 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | Fair |
| #15888 | Farahvar et al. | 2011 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | Good |

Column header legend: 1= Representativeness of the Exposed Cohort, 2= Selection of the Non-Exposed Cohort, 3= Ascertainment of Exposure, 4= Demonstration that Outcome of Interest Was Not Present at Start of Study, 5= Comparability of Cases and Controls on the Basis of the Design or Analysis, 6= Assessment of Outcome, 7= Was Follow-Up Long Enough for Outcomes to Occur, 8= Adequacy of Follow Up of Cohorts, 9= Total Score.

eTable 6: Heterogeneity analysis for continuous variables

| Variable | I2 | R2 | p-value |
|----------------|-------|-------|---------|
| 1. Sample size | 91.48 | 7.62 | 0.07 |
| 2. Male % | 90.58 | 7.34 | 0.03 |
| 3. BP cutoff | 89.37 | 26.53 | 0.001 |
| 4. Mean age | 92.02 | 0 | 0.43 |

eTable 7: Heterogeneity analysis for categorical variables

| Group | tau2 | 12 |
|----------------------|-------|----------------|
| Sample size category | tau2 | 14 |
| 1001-5000 | 0.121 | 83.24 |
| 200-1000 | 0.121 | 85·24 85·20 |
| | 0.329 | 0 |
| <200 | 0.000 | 94·05 |
| >5000 | 0.138 | 94.05 |
| BP category | | |
| 90 | 0.244 | 92.04 |
| <90 | 0.000 | 0 |
| >90 | 0.046 | 82.20 |
| TBI severity | | |
| Both | 0.363 | 88.47 |
| Moderate | 0.000 | 0 |
| Severe | 0.181 | 92.52 |
| TBI scale | | |
| AIS | 0.151 | 92.01 |
| GCS | 0.278 | 91.20 |
| Hypoxia adjusted | | |
| No | 0.318 | 95.82 |
| Yes | 0.053 | 71.47 |
| Location | | |
| ALL | 0.270 | 88.54 |
| ED | 0.273 | 92.61 |
| EMS | 0.065 | 81.52 |
| ICU | 0.451 | 65.70 |
| Trauma type | | |
| Isolated | 0.495 | 97.10 |
| Polytrauma | 0.131 | 89.01 |
| Age category | | |
| 40-50 | 0.131 | 84.19 |
| 50-60 | 0.175 | 94.34 |
| <40 | 0.289 | 91.77 |
| >60 | 0.016 | 26.60 |
| Combined 1-3 | 0.186 | 92.21 |
| comonica i o | 0 100 | / 1 |

eTable 8: Leave one out analysis for studies reporting adjusted OR (60 studies)

Exp(theta) is the overall adjusted OR

| Exp(theta) is the overall adjusted OR. | | | | | | | | |
|--|------------|----------------------|---------|--|--|--|--|--|
| Omitted study | exp(theta) | [95% conf. interval] | p-value | | | | | |
| Aiolfi 2017 | 2.216 | 1.952-2.516 | 0.001 | | | | | |
| Aiolfi 2018 | 2.146 | 1.914-2.407 | 0.001 | | | | | |
| Czorlich 2017 | 2.219 | 1.956-2.519 | 0.001 | | | | | |
| DuBose 2008 | 2.241 | 1.977-2.540 | 0.001 | | | | | |
| Farahvar 2011 | 2.218 | 1.954 -2.516 | 0.001 | | | | | |
| Farahvar 2012 | 2.221 | 1.957-2.521 | 0.001 | | | | | |
| Franschman 2011 | 2.206 | 1.946-2.499 | 0.001 | | | | | |
| Fuller 2014 (a) | 2.199 | 1.943-2.490 | 0.001 | | | | | |
| Fuller 2014 (b) | 2.209 | 1.950-2.503 | 0.001 | | | | | |
| Fuller 2014 (c) | 2.212 | 1.951-2.507 | 0.001 | | | | | |
| Fuller 2014 (d) | 2.221 | 1.958-2.519 | 0.001 | | | | | |
| Fuller 2014 (e) | 2.225 | 1.961-2.524 | 0.001 | | | | | |
| Huang 2022 (a) | 2.212 | 1.953-2.505 | 0.001 | | | | | |
| Huang 2022 (b) | 2.228 | 1.967-2.524 | 0.001 | | | | | |
| Hukkelhoven 2005 | 2.219 | 1.954-2.519 | 0.001 | | | | | |
| Jacobs 2013 | 2.210 | 1.950-2.506 | 0.001 | | | | | |
| Kamal 2016 | 2.175 | 1.927-2.456 | 0.001 | | | | | |
| Kamal 2021 | 2.158 | 1.919-2.426 | 0.001 | | | | | |
| Khalili 2017 | 2.164 | 1.922-2.436 | 0.001 | | | | | |
| Krishnamoorthy 2015 | 2.230 | 1.965-2.531 | 0.001 | | | | | |
| Lenstra 2020 | 2.208 | 1.949-2.501 | 0.001 | | | | | |
| Merck 2019 | 2.238 | 1.974-2.536 | 0.001 | | | | | |
| Newgard 2015 (a) | 2.228 | 1.964-2.527 | 0.001 | | | | | |
| Newgard 2015 (b) | 2.248 | 1.989-2.541 | 0.001 | | | | | |
| Newgard 2015 (c) | 2.253 | 1.997-2.542 | 0.001 | | | | | |
| Petroni 2010 | 2.207 | 1.949-2.499 | 0.001 | | | | | |
| Rice 2023 (a) | 2.227 | 1.962-2.528 | 0.001 | | | | | |
| Rice 2023 (b) | 2.211 | 1.949-2.509 | 0.001 | | | | | |
| Rice 2023 (c) | 2.190 | 1.934-2.479 | 0.001 | | | | | |
| Schellenberg 2021 | 2.210 | 1.949-2.505 | 0.001 | | | | | |
| Shibahashi 2017 | 2.215 | 1.952-2.513 | 0.001 | | | | | |
| Shibahashi 2018 (a) | 2.234 | 1.969-2.535 | 0.001 | | | | | |
| Shibahashi 2018 (b) | 2.238 | 1.974-2.537 | 0.001 | | | | | |
| Shibahashi 2018 (c) | 2.235 | 1.970-2.535 | 0.001 | | | | | |
| Shibahashi 2018 (d) | 2.222 | 1.957-2.522 | 0.001 | | | | | |
| Shibahashi 2018 (e) | 2.209 | 1.946-2.507 | 0.001 | | | | | |
| Shibahashi 2018 (f) | 2.205 | 1.944-2.502 | 0.001 | | | | | |
| Shibahashi 2021 (a) | 2.236 | 1.971-2.536 | 0.001 | | | | | |
| Shibahashi 2021 (b) | 2.245 | 1.983-2.542 | 0.001 | | | | | |
| Shibahashi 2021 (c) | 2.233 | 1.968-2.534 | 0.001 | | | | | |
| Shibahashi 2021 (d) | 2.225 | 1.960-2.526 | 0.001 | | | | | |
| Shibahashi 2021 (e) | 2.212 | 1.949-2.511 | 0.001 | | | | | |
| Shibahashi 2021 (f) | 2.210 | 1.947-2.508 | 0.001 | | | | | |
| Spaite 2017 (1128) | 2.243 | 1.980-2.541 | 0.001 | | | | | |
| Spaite 2017 (1222) | 2.213 | 1.950-2.512 | 0.001 | | | | | |
| Spaite 2017 (a) | 2.198 | 1.940-2.489 | 0.001 | | | | | |
| Spaite 2017 (b) | 2.207 | 1.946-2.503 | 0.001 | | | | | |
| Spaite 2017 (c) | 2.217 | 1.953-2.516 | 0.001 | | | | | |
| Spaite 2017 (d) | 2.211 | 1.949-2.510 | 0.001 | | | | | |
| Spaite 2017 (e) | 2.211 | 1.949-2.509 | 0.001 | | | | | |
| Spaite 2017 (f) | 2.223 | 1.958-2.523 | 0.001 | | | | | |
| Spaite 2017 (g) | 2.223 | 1.958-2.523 | 0.001 | | | | | |
| Spaite 2017 (h) | 2.221 | 1.956-2.521 | 0.001 | | | | | |
| Spaite 2017 (i) | 2.223 | 1.958-2.524 | 0.001 | | | | | |
| Spaite 2017 (j) | 2.225 | 1.960-2.526 | 0.001 | | | | | |
| Spaite 2017 (k) | 2.230 | 1.965-2.531 | 0.001 | | | | | |
| Spaite 2017 (1) | 2.233 | 1.968-2.533 | 0.001 | | | | | |
| Spaite 2017 (m) | 2.233 | 1.968-2.533 | 0.001 | | | | | |
| Tohme 2014 | 2.219 | 1.956-2.517 | 0.001 | | | | | |
| Zafar 2011 | 2.209 | 1.947-2.507 | 0.001 | | | | | |
| exp(theta) | 2.217 | 1.958-2.510 | 0.001 | | | | | |
| | | | | | | | | |

Fuller 2014 sub-studies include different hypotension thresholds of a) 70mmHg, b) 80mmHg, c) 90 mmHg, d)100mmHg, e)110mmHg. Huang 2022 sub-studies include a) moderate TBI) and b) severe TBI. Newgard 2015 sub-studies include different hypotension thresholds of a) <90mmHg, b) 90-105mmHg, c) 105-120mmHg. Rice 2023 sub-studies include blood pressure measurement in a) EMS, b) ED, c) EMS and ED. Shibahashi 2018 and 2021 sub-studies include different blood pressure thresholds of a) 100-109mmHg, b) 90-99mmHg, c) 80-89mmHg, d) 70-79mmHg, e) <70mmHg, f) <110mmHg. Spaite 2017 sub-studies include blood pressure thresholds increments of 5mmHg from a) <60mmHg to m) <120mmHg.

eTable 9: Leave one out analysis for studies reporting crude OR (50 studies)


| Omitted study | Crude HR | [95% conf. interval] | p-value |
|--|----------------|----------------------|---------|
| Chamoun 2009 | 3.888 | 3.082-4.906 | 0.001 |
| Corral 2012 | 3.812 | 3.013-4.822 | 0.001 |
| Franschman 2011 | 3.828 | 3.026-4.842 | 0.001 |
| Fuller 2014 (a) | 3.688 | 2.947-4.616 | 0.001 |
| Fuller 2014 (b) | 3.741 | 2.967-4.716 | 0.001 |
| Fuller 2014 (c) | 3.805 | 3.007-4.815 | 0.001 |
| Fuller 2014 (d) | 3.845 | 3.039-4.865 | 0.001 |
| Fuller 2014 (e) | 3.884 | 3.076-4.906 | 0.001 |
| Heppekcan 2019 | 3.761 | 2.982-4.744 | 0.001 |
| Herrera-Melero 2015 | 3.865 | 3.057-4.886 | 0.001 |
| Huang 2022 (a) | 3.817 | 3.026-4.814 | 0.001 |
| Huang 2022 (b) | 3.886 | 3.083-4.897 | 0.001 |
| Kamal 2016 | 3.721 | 2.957-4.681 | 0.001 |
| Kamal 2021 | 3.705 | 2.951-4.651 | 0.001 |
| Kim 2018 (a) | 3.845 | 3.043- 4.859 | 0.001 |
| Kim 2018 (b) | 3.858 | 3.054- 4.872 | 0.001 |
| Krishnamoorthy 2015 | 3.810 | 3.010-4.822 | 0.001 |
| Lenstra 2020 | 3.849 | 3.045-4.865 | 0.001 |
| Manley 2001 | 3.829 | 3.029-4.840 | 0.001 |
| Muehlschlegel 2013 | 3.819 | 3.019-4.832 | 0.001 |
| Newgard 2015 (a) | 3.869 | 3.061-4.889 | 0.001 |
| Newgard 2015 (b) | 3.946 | 3.144-4.953 | 0.001 |
| Newgard 2015 (c) | 3.972 | 3.175-4.969 | 0.001 |
| Para 2018 | 3.777 | 2.993-4.766 | 0.001 |
| Petroni 2010 | 3.780 | 2.995-4.771 | 0.001 |
| Pin-On 2017 (a) | 3.840 | 3.041-4.848 | 0.001 |
| Pin-On 2017 (b) | 3.847 | 3.049-4.855 | 0.001 |
| Pin-On 2017 (c) | 3.888 | 3.086-4.898 | 0.001 |
| Pin-On 2017 (d) | 3.780 | 2.997-4.767 | 0.001 |
| Rauch 2021 | 3.863 | 3.056-4.882 | 0.001 |
| Rice 2023 (BOTH) | 3.707 | 2.952-4.656 | 0.001 |
| Rice 2023 (ED) | 3.747 | 2.969-4.729 | 0.001 |
| Rice 2023 (EMS) | 3.813 | 3.012-4.828 | 0.001 |
| Shafi 2005 (ED) | 3.758 | 2.975-4.748 | 0.001 |
| Shafi 2005 (EMS) | 3·715 | 2.955-4.670 | 0.001 |
| Shibahashi 2021 (a) | 3.923 | 3.116-4.939 | 0.001 |
| Shibahashi 2021 (b) | 3.786 | 2.993-4.789 | 0.001 |
| Shibahashi 2021 (c) | 3.816 | 3.014-4.831 | 0.001 |
| Shibahashi 2021 (d) | 3.846 | 3.040-4.868 | 0.001 |
| Shibahashi 2021 (d) Shibahashi 2021 (e) | 3.885 | 3.076-4.907 | 0.001 |
| Shibahashi 2021 (e) Shibahashi 2021 (overall) | 3.887 | 3.077-4.909 | 0.001 |
| Shibahasi 2017 | 3.864 | 3.056-4.885 | 0.001 |
| Song 2023 (a) | 3.891 | 3.082-4.912 | 0.001 |
| | 3.779 | 2.988-4.779 | 0.001 |
| Spaite 2017 (1128) | 3·7/9 3·808 | 3·008-4·820 | 0.001 |
| Spaite 2017 (1222) Spaite 2022 | 3·808 3·788 | 2.994-4.793 | 0.001 |
| | | | |
| Tohme 2014 | 3.849 | 3.044-4.867 | 0.001 |
| Vos 2010 | 3.889 | 3.086-4.900 | 0.001 |
| Yeung 2011 | 3.715 | 2.955-4.670 | 0.001 |
| Zeiler 2021 | 3.857 | 3.054-4.871 | 0.001 |
| exp(theta) | 3.822 | 3.036-4.813 | 0.001 |

Fuller 2014 sub-studies include different hypotension thresholds of a) 70mmHg, b) 80mmHg, c) 90 mmHg, d)100mmHg. Huang 2022 sub-studies include a) moderate TBI) and b) severe TBI. Kim 2018 sub-studies include blood pressure thresholds of a) <90mmHg and b) <110 mmHg. Newgard 2015 sub-studies include different hypotension thresholds of a) <90mmHg, b) 90-105mmHg, c) 105-120mmHg. Pin-On 2017 sub-studies include a) severe TBI, blood pressure <20% baseline measured during induction, b) severe TBI, blood pressure <20% baseline measured intra-operatively, c) moderate TBI, blood pressure <90mmHg measured during induction, d) moderate TBI, blood pressure <90mmHg measured intra-operatively. Shibahashi 2021 sub-studies include different blood pressure thresholds of a) 100-109mmHg, b) 90-99mmHg, c) 80-89mmHg, d) 70-79mmHg, e) <70mmHg.

eTable 10: Heterogeneity analysis for sub-studies using multi-level meta-analysis


| Assumption | Effect estimate (95% CI) | Heterogeneity (%) |
|-----------------------------------|--------------------------|-------------------|
| No dependence | 2.22 (1.96-2.51) | 92 |
| Dependence (multiplicative model) | 2.60 (2.01-3.35) | 77 |
| No sub-studies (sensitivity) | 2.96 (2.22-3.94) | 92 |

eFigure 1: Forest plot showing crude association of hypotension on adverse outcome (vegetative state/mortality) in patients with moderate to severe traumatic brain injury (Effect estimate=unadjusted odds ratio) (50 studies)



Legend: Fuller 2014 sub-studies include different hypotension thresholds of a) 70mmHg, b) 80mmHg, c) 90 mmHg, d)100mmHg e)110mmHg. Kim 2018 sub-studies include blood pressure thresholds of a) <90mmHg and b) <110 mmHg. Newgard 2015 sub-studies include different hypotension thresholds of a) <90mmHg, b) 90-105mmHg, c) 105-120mmHg. Pin-On 2017 sub-studies include a) severe TBI, blood pressure <20% baseline measured during induction, b) severe TBI, blood pressure <20% baseline measured intra-operatively, c) moderate TBI, blood pressure <90mmHg measured during induction, d) moderate TBI, blood pressure <90mmHg measured intra-operatively.

eFigure 2: Forest plot showing incidence of hypotension by subgroups in patients with moderate to severe traumatic brain injury (44 studies)




Legend: K indicates the number of studies. Vertical red line indicates line of no effect. Green diamond indicates an overall pooled effect. Horizontal red lines indicate 95% confidence interval of respective study.

eFigure 3: Forest plot showing association of hypotension on adverse outcome (vegetative state/mortality) in patients with moderate to severe traumatic brain injury (effect estimate=adjusted odds ratio) (67 studies with or without complete data on sample size)

| Study | | adj OR with 95% CI | Weigl (%) |
|--|-------------------|--|--------------|
| Nolfi 2017 | | 2.34 [1.88, 2.91] | 1.78 |
| Nolfi 2018 | - | 7.31 [6.03, 8.87] | 1.81 |
| Asmar 2021 (a) | - | 1.18 [0.84, 1.66] | 1.64 |
| Asmar 2021 (b) | - | 1.75 [1.09, 2.81] | |
| Asmar 2021 (c) | | 3.20 [1.64, 6.26] | |
| Asmar 2021 (d) | | 1.42 [1.27, 1.58] | |
| Asmar 2021 (e) | | 2.36 [2.07, 2.69] | |
| Asmar 2021 (f) | _ | 3.59 [3.01, 4.29] | |
| Chen 2019 | — <u> </u> | 1.07 [1.03, 1.11] | |
| Czorlich 2017 | | 2.14 [1.38, 3.31] | |
| OuBose 2008 | | 1.32 [1.14, 1.53] | |
| arahvar 2011 | | 2.25 [1.42, 3.57] | |
| Farahvar 2012 Franschman 2011 | | 2.08 [1.48, 2.92] 3.57 [1.52, 8.37] | 0.95 |
| | | | |
| Fuller 2014 (a) Fuller 2014 (b) | | 5.90 [1.89, 18.41] 3.50 [1.10, 11.12] | |
| Fuller 2014 (b) | | 2.90 [1.10, 7.62] | |
| Fuller 2014 (d) | | 2.00 [0.98, 4.10] | |
| Fuller 2014 (e) | | 1.80 [1.01, 3.22] | |
| Huang 2022 (a) | | 5.15 [0.57, 46.59] | |
| luang 2022 (a) | | 1.04 [0.30, 3.64] | |
| Hukkelhoven 2005 | T 📥 | 2.20 [1.68, 2.87] | |
| acobs 2013 | | 2.90 [1.31, 6.43] | 1.01 |
| acous 2013 (amal 2016 | | 5.80 [3.77, 8.93] | 1.51 |
| Carnal 2016 | | 8.30 [5.26, 13.10] | 1.48 |
| Chalili 2017 | | 9.82 [5.20, 18.56] | 1.22 |
| Crishnamoorthy 2015 | _ | 1.71 [1.37, 2.13] | 1.78 |
| enstra 2020 | | 4.13 [1.16, 14.74] | 0.59 |
| Merck 2019 | - | 1.28 [0.83, 1.98] | 1.51 |
| lewgard 2015 (a) | - | 1.61 [0.87, 2.97] | 1.25 |
| lewgard 2015 (b) | _ | 0.79 [0.45, 1.39] | 1.32 |
| Newgard 2015 (c) | - | 0.73 [0.46, 1.15] | |
| Petroni 2010 | - | 6.21 [1.14, 33.90] | |
| Rice 2023 (a) | - | 1.80 [1.39, 2.33] | |
| Rice 2023 (b) | - | 2.61 [1.73, 3.94] | 1.54 |
| Rice 2023 (c) | - | 4.36 [2.78, 6.84] | 1.49 |
| Schellenberg 2021 | | 2.93 [1.41, 6.09] | 1.09 |
| Shibahashi 2017 | - | 2.42 [1.41, 4.15] | 1.36 |
| Shibahashi 2018 (a) | | 1.58 [1.42, 1.76] | 1.87 |
| Shibahashi 2018 (b) | - | 1.40 [1.13, 1.73] | 1.79 |
| Shibahashi 2018 (c) | - | 1.51 [1.20, 1.90] | 1.77 |
| Shibahashi 2018 (d) | | 2.06 [1.61, 2.63] | 1.75 |
| Shibahashi 2018 (e) | - | 2.71 [2.10, 3.49] | 1.75 |
| Shibahashi 2018 (f) | - | 2.94 [2.20, 3.92] | 1.70 |
| Shibahashi 2021 (a) | | 1.52 [1.40, 1.66] | 1.88 |
| Shibahashi 2021 (b) | | 1.18 [1.01, 1.38] | 1.84 |
| Shibahashi 2021 (c) | | 1.59 [1.34, 1.88] | 1.83 |
| Shibahashi 2021 (d) | - | 1.91 [1.57, 2.32] | 1.81 |
| Shibahashi 2021 (e) | <u> </u> | 2.55 [2.02, 3.22] | 1.77 |
| shibahashi 2021 (f) | | 2.68 [2.02, 3.55] | 1.71 |
| Spaite 2017 (1128) | | 1.27 [1.17, 1.37] | 1.88 |
| Spaite 2017 (1222) | - | 2.49 [1.87, 3.32] | 1.71 |
| paite 2017 (a) | | 4.30 [2.09, 8.85] | 1.10 |
| paite 2017 (b) | 1 1 | 3.00 [1.73, 5.20] | 1.34 |
| Spaite 2017 (c) | 🛨 | 2.30 [1.48, 3.56] | 1.50 |
| Spaite 2017 (d) | | 2.60 [1.79, 3.78] | 1.59 |
| Spaite 2017 (e) | | 2.60 [1.86, 3.63] | |
| Spaite 2017 (f) Spaite 2017 (g) | | 2.00 [1.52, 2.63] 2.00 [1.52, 2.63] | |
| Spaite 2017 (g) Spaite 2017 (h) | I | 2.00 [1.52, 2.63] 2.10 [1.65, 2.68] | 1.72 |
| Spaite 2017 (h) Spaite 2017 (i) | | 2.10 [1.65, 2.68] | |
| Spaite 2017 (i) Spaite 2017 (j) | | 2.00 [1.60, 2.50] 1.90 [1.53, 2.35] | |
| Spaite 2017 (j) Spaite 2017 (k) | | 1.90 [1.53, 2.35] | |
| Spaite 2017 (K) | | 1.70 [1.39, 2.08] | |
| Spaite 2017 (I) | | 1.60 [1.29, 1.98] | |
| Sparte 2017 (m) Sphrne 2014 | | 2.13 [1.12, 4.05] | |
| onme 2014 Zafar 2011 | | 2.13 [1.12, 4.05] | |
| | | | 1.75 |
| Overall | ₹ | 2.17 [1.93, 2.44] | |
| Heterogeneity: τ ² = 0.19, I ² = 94.74%, H ² = 19.00 | | | |
| act of 0 - 0 : O(66) - 1175 40 - 0.00 | | | |
| Test of $\theta_i = \theta_j$: Q(66) = 1175.46, p = 0.00 Test of θ = 0: z = 12.94, p = 0.00 | | | |


Legend: Asmar 2021 sub-studies include a) moderate TBI and blood pressure 90-109mmHg, b) moderate TBI and blood pressure 70-90mmHg, c) moderate TBI and blood pressure <70mmHg, d) severe TBI and blood pressure 90-109mmHg, e) severe TBI and blood pressure 70-90mmHg, f) severe TBI and blood pressure <70mmHg. Fuller 2014 sub-studies include different hypotension thresholds of a) 70mmHg, b) 80mmHg, c) 90 mmHg, d)100mmHg e)110mmHg. Huang 2022 sub-studies include a) moderate TBI) and b) severe TBI. Newgard 2015 sub-studies include different hypotension thresholds of a) <90mmHg, b) 90-105mmHg, c) 105-120mmHg. Rice 2023 sub-studies include blood pressure measurement in a) EMS, b) ED, c) EMS and ED. Shibahashi 2018 and 2021 sub-studies include different blood pressure thresholds of a) <110mmHg, b) 100-109mmHg, c) 90-99mmHg, d) 80-89mmHg e) 70-79mmHg, f) <70mmHg. Spaite 2017 sub-studies include blood pressure thresholds increments of 5mmHg from a) <60mmHg to m) <120mmHg.

eFigure 4: Funnel plot (contour-enhanced) for publication bias.




Legend: Blue dots represent individual studies. Shades of grey represent different p values. Red line indicates estimated theta random effects model.

eFigure 5: Galbraith Plot for exhibiting outliers.



Legend: Blue dots represent individual studies. Black indicates 95% CI. Red line indicates regression line.

eFigure 6: Trim fill funnel plot for publication bias.



Legend: Blue dots represent observed studies. Yellow dots represent imputed studies. White lines represent pseudo 95% confidence intervals. Red line represents estimated theta random effects model.